Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

GlaxoSmithKline Pharmaceuticals Ltd

NSE: GLAXO · BSE: 500660 · Pharmaceuticals & Biotechnology · 34 announcements

Share price
₹2,628.40
Market cap
₹44,527 Cr
Revenue (annual)
₹3,822 Cr
Net profit (annual)
₹1,036 Cr
P/E (TTM)
41.7×Sector 47.4×
Promoter holding
75.00%+0.00% QoQ
FII holding
4.79%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

20:41 IST BSE
Management Change

GlaxoSmithKline Pharmaceuticals Management Change

GSK Pharmaceuticals reported the resignation of Director Subesh Williams and the re-appointment of Executive Director Bhushan Akshikar effective December 1, 2026.

12:38 IST BSE
Management Change

GlaxoSmithKline Pharmaceuticals Management Change

Dr. Simrat Sohal resigned as Compliance Officer of GlaxoSmithKline Pharmaceuticals, effective August 5, 2026. This transition requires the company to appoint a successor for regulatory compliance.

11:11 IST NSE
Management Change

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Limited appointed Mr. Vinay Subramanian as Commercial Head - Oncology, effective April 20, 2026. Mr. Subramanian brings 24 years of experience from Roche, GE Healthcare, and Pfizer. This leadership addition strengthens the company's oncology portfolio management and strategic business development in India.

10:50 IST NSE
Management Change

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Limited has appointed Mr. Ronojit Biswas as an Executive Director for a three-year term starting April 1, 2026. A seasoned finance leader with over 25 years of global GSK experience, he previously served as CFO for GSK's Brazil and Vietnam operations.

Execution
36 months
10:31 IST BSE
Management Change

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Ltd appointed Mr. Vinay Subramanian as Commercial Head – Oncology and Senior Management Personnel, effective April 20, 2026. Subramanian brings over 24 years of experience from Roche, GE Healthcare, and Pfizer. This leadership addition strengthens the company's oncology business segment and strategic management team in Mumbai.